JP2018511613A5 - - Google Patents

Download PDF

Info

Publication number
JP2018511613A5
JP2018511613A5 JP2017552060A JP2017552060A JP2018511613A5 JP 2018511613 A5 JP2018511613 A5 JP 2018511613A5 JP 2017552060 A JP2017552060 A JP 2017552060A JP 2017552060 A JP2017552060 A JP 2017552060A JP 2018511613 A5 JP2018511613 A5 JP 2018511613A5
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
cancer
diazaspiro
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017552060A
Other languages
English (en)
Japanese (ja)
Other versions
JP6737533B2 (ja
JP2018511613A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/025345 external-priority patent/WO2016161160A1/en
Publication of JP2018511613A publication Critical patent/JP2018511613A/ja
Publication of JP2018511613A5 publication Critical patent/JP2018511613A5/ja
Application granted granted Critical
Publication of JP6737533B2 publication Critical patent/JP6737533B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017552060A 2015-04-03 2016-03-31 スピロ環式化合物 Expired - Fee Related JP6737533B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562142946P 2015-04-03 2015-04-03
US62/142,946 2015-04-03
PCT/US2016/025345 WO2016161160A1 (en) 2015-04-03 2016-03-31 Spirocyclic compounds

Publications (3)

Publication Number Publication Date
JP2018511613A JP2018511613A (ja) 2018-04-26
JP2018511613A5 true JP2018511613A5 (enExample) 2019-05-09
JP6737533B2 JP6737533B2 (ja) 2020-08-12

Family

ID=57007413

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017552060A Expired - Fee Related JP6737533B2 (ja) 2015-04-03 2016-03-31 スピロ環式化合物

Country Status (25)

Country Link
US (3) US10525036B2 (enExample)
EP (1) EP3277690B1 (enExample)
JP (1) JP6737533B2 (enExample)
KR (1) KR20170132307A (enExample)
CN (1) CN107849053B (enExample)
AU (1) AU2016242940B2 (enExample)
BR (1) BR112017021194A2 (enExample)
CA (1) CA2981055A1 (enExample)
CY (1) CY1123019T1 (enExample)
DK (1) DK3277690T3 (enExample)
ES (1) ES2788160T3 (enExample)
HR (1) HRP20200805T1 (enExample)
HU (1) HUE049481T2 (enExample)
IL (1) IL254662B (enExample)
LT (1) LT3277690T (enExample)
MX (1) MX379622B (enExample)
PL (1) PL3277690T3 (enExample)
PT (1) PT3277690T (enExample)
RS (1) RS60340B1 (enExample)
RU (1) RU2745069C2 (enExample)
SG (1) SG11201707911VA (enExample)
SI (1) SI3277690T1 (enExample)
SM (1) SMT202000279T1 (enExample)
TW (1) TWI705067B (enExample)
WO (1) WO2016161160A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106999451B (zh) * 2014-09-17 2021-04-02 里科瑞尔姆Ip控股有限责任公司 双环化合物
ES2788160T3 (es) 2015-04-03 2020-10-20 Recurium Ip Holdings Llc Compuestos espirocíclicos
US10934304B2 (en) 2016-10-05 2021-03-02 Recurium Ip Holdings, Llc Spirocyclic compounds
BR112019011801A2 (pt) 2016-12-08 2019-10-29 Univ Texas composto, composição farmacêutica e método de inibição de dlk, método de tratamento de uma doença mediada por dlk, método de tratamento de câncer e redução do desenvolvimento de um distúrbio neurológico induzido por quimioterapia e método para alcançar um efeito em um paciente
AU2019215049A1 (en) * 2018-01-31 2020-09-17 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
NZ780966A (en) 2019-04-18 2026-02-27 Univ Johns Hopkins Substituted 2-amino-pyrazolyl-[1,2,4]triazolo[1,5a] pyridine derivatives and use thereof
US11560366B2 (en) 2019-10-21 2023-01-24 Board Of Regents, The University Of Texas System Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease
IL301817A (en) 2020-10-13 2023-06-01 Univ Johns Hopkins Modified 4-([4,2,1]triazolo[5,1-a]pyridin-6-yl)thiophene-2-carboxamide histories and their use
CN115124542A (zh) * 2022-07-08 2022-09-30 河南师范大学 羟基苯取代吡唑酮并吲唑[螺]吡唑酮类化合物的合成方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057579A1 (es) * 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
EP2086974B1 (en) 2006-11-17 2013-07-24 Polyera Corporation Diimide-based semiconductor materials and methods of preparing and using the same
RU2525389C2 (ru) 2008-02-21 2014-08-10 Мерк Шарп И Доум Корп. Соединения, которые являются ингибиторами erk
EP2318388A2 (en) 2008-07-23 2011-05-11 Schering Corporation Tricyclic spirocycle derivatives and methods of use thereof
JP2013506669A (ja) * 2009-09-30 2013-02-28 メルク・シャープ・アンド・ドーム・コーポレーション Erk阻害剤である新規化合物
WO2011071860A2 (en) 2009-12-07 2011-06-16 Alnylam Pharmaceuticals, Inc. Compositions for nucleic acid delivery
US8664213B2 (en) 2011-08-29 2014-03-04 Bristol-Myers Squibb Company Spiro bicyclic diamine derivatives as HIV attachment inhibitors
CN103130775B (zh) * 2011-11-22 2015-09-30 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的吲哚满酮衍生物
US8987264B2 (en) * 2012-11-09 2015-03-24 Bristol-Myers Squibb Company 1,3,5-triazine derivatives of spiro bicyclic oxalamide-compounds for treatment of hepatitis C
US9447025B2 (en) 2013-03-14 2016-09-20 Kalyra Pharmaceuticals, Inc. Bicyclic analgesic compounds
CN105732636B (zh) 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
ES2788160T3 (es) 2015-04-03 2020-10-20 Recurium Ip Holdings Llc Compuestos espirocíclicos
US10934304B2 (en) 2016-10-05 2021-03-02 Recurium Ip Holdings, Llc Spirocyclic compounds

Similar Documents

Publication Publication Date Title
RU2017133973A (ru) Спироциклические соединения
JP2018530591A5 (enExample)
JP7676141B2 (ja) ジヒドロオキサジアジノン
IL187690A (en) Derivatives 1, 2, 4 - Triazolo - 1, 6 - Naphthiridines as inhibitors of AKT activity for use in the preparation of drugs for the treatment of cancer
JP2009524670A5 (enExample)
JP2007510689A5 (enExample)
JP2012532931A5 (enExample)
IL258577A (en) 2,4-dihydroxy-nicotinamides as apj agonists
JP2020515575A5 (enExample)
RU2019132212A (ru) Селективные ингибиторы hdac6
JP2021500335A5 (enExample)
RU2016133684A (ru) Бициклические азот-содержащие соединения как агонисты М1 мускариновых рецепторов
JP2018522046A5 (enExample)
JP2011507849A5 (enExample)
JP2018535999A5 (enExample)
JP2009541311A5 (enExample)
IL263511A (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
EP3661560A1 (en) Combination of atr kinase inhibitors and pd-1/pd-l1 inhibitors
CA2642922A1 (en) Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
JP2017530185A5 (enExample)
JP2020520925A5 (enExample)
RU2012134306A (ru) Азотосодержащие производные гетероарилов
JP2018520201A5 (enExample)
JP2014510708A5 (enExample)
JP2010539180A5 (enExample)